Judit Fernández Fuertes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Judit Fernández Fuertes has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Andrea Acebes-Huerta
Platelet Research Lab, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain; Dept. of Medicine, University of Oviedo, Spain
3 shared publications- Laura Gutiérrez
Platelet Research Lab, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain
3 shared publications Luis Rafael Ramos Pascua
Servicio de COT, Hospital Universitario de León, León, España
2 shared publicationsMaría Carmen Muñoz-Turrillas
Platelet Research Lab, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain; Centro Regional de Transfusión de Toledo-Guadalajara
2 shared publicationsSergio Sánchez Herráez
Servicio de COT, Hospital Universitario de León, León, España
2 shared publicationsTamara Arias-Fernández
Platelet Research Lab, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Asturias, Spain
2 shared publications
Latest Publications
- 28 October 2026
- Published by Elsevier in Rehabilitación
- Vol. 60 (4)
Factors associated with 120-day mortality, functional decline, and residential status following fragility hip fractures: A prospective cohort study
- 28 October 2026
- Published by Elsevier in Rehabilitación
- Vol. 60 (4)
Factors associated with 120-day mortality, functional decline, and residential status following fragility hip fractures: A prospective cohort study
- Open Access
- 3 February 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 177, 132-147
Characterization of the molecular composition and in vitro regenerative capacity of platelet-based bioproducts and related subfractions
- 3 February 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 177, 132-147
Open AccessCharacterization of the molecular composition and in vitro regenerative capacity of platelet-based bioproducts and related subfractions
- Open Access
- 1 March 2022
- Published by SAGE Publications in Orthopaedic Journal of Sports Medicine
- Vol. 10 (3)
Clinical Response After Treatment of Knee Osteoarthritis With a Standardized, Closed-System, Low-Cost Platelet-Rich Plasma Product: 1-Year Outcomes
Background: Intra-articular infiltration of platelet-rich plasma (PRP) is an alternative therapeutic option to classic hyaluronic acid for the treatment of symptomatic knee osteoarthritis (KOA). However, variation in preparation methods and quality assessment of PRP makes the study of its real clinical efficacy difficult. Purpose: To (1) evaluate the clinical efficacy of a characterized PRP product prepared in a standardized manner and in a closed-system for the treatment of KOA and to (2) evaluate the association of the clinical response to PRP-related variables. Study Design: Case series; Level of evidence, 4. Methods: We recruited 130 patients with nonoperative KOA and evaluated them for 1 year. PRP was prepared from a donation of autologous blood, obtaining 3 aliquots of approximately 10mL of product, which were frozen, allowing platelet disruption, platelet factor release, and long-term storage, until administration. Patients were treated 3 consecutive times every 4 weeks with an intra-articular PRP knee injection under sterile conditions. Complete blood count was performed on the whole-blood sample and the processed PRP before freezing it, for product quality assessment. Patients were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and basic satisfaction scale at 3 months, 6 months, and 1 year after intervention. Results: Quality assessment confirmed a leukocyte-poor PRP product (white blood cell count, 0.09 ± 0.09 × 109/L) with a high platelet purity (platelet count, 630.86 ± 191.75 × 109/L). WOMAC scores improved, and basic satisfaction was achieved in 70% of patients. No adverse events were reported. No correlations were observed between PRP quality parameters and clinical results. PRP complete treatment production costs were €108/US$125 (€36/US$41.6 per injection). Conclusion: This standardized PRP production method resulted in improved WOMAC scores at 1 year postoperatively in 70% of patients with KOA. This technique was safe and affordable and ensured consecutive infiltrations with the same product to each patient.
- 1 March 2022
- Published by SAGE Publications in Orthopaedic Journal of Sports Medicine
- Vol. 10 (3)
Open AccessClinical Response After Treatment of Knee Osteoarthritis With a Standardized, Closed-System, Low-Cost Platelet-Rich Plasma Product: 1-Year Outcomes
Background: Intra-articular infiltration of platelet-rich plasma (PRP) is an alternative therapeutic option to classic hyaluronic acid for the treatment of symptomatic knee osteoarthritis (KOA). However, variation in preparation methods and quality assessment of PRP makes the study of its real clinical efficacy difficult. Purpose: To (1) evaluate the clinical efficacy of a characterized PRP product prepared in a standardized manner and in a closed-system for the treatment of KOA and to (2) evaluate the association of the clinical response to PRP-related variables. Study Design: Case series; Level of evidence, 4. Methods: We recruited 130 patients with nonoperative KOA and evaluated them for 1 year. PRP was prepared from a donation of autologous blood, obtaining 3 aliquots of approximately 10mL of product, which were frozen, allowing platelet disruption, platelet factor release, and long-term storage, until administration. Patients were treated 3 consecutive times every 4 weeks with an intra-articular PRP knee injection under sterile conditions. Complete blood count was performed on the whole-blood sample and the processed PRP before freezing it, for product quality assessment. Patients were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and basic satisfaction scale at 3 months, 6 months, and 1 year after intervention. Results: Quality assessment confirmed a leukocyte-poor PRP product (white blood cell count, 0.09 ± 0.09 × 109/L) with a high platelet purity (platelet count, 630.86 ± 191.75 × 109/L). WOMAC scores improved, and basic satisfaction was achieved in 70% of patients. No adverse events were reported. No correlations were observed between PRP quality parameters and clinical results. PRP complete treatment production costs were €108/US$125 (€36/US$41.6 per injection). Conclusion: This standardized PRP production method resulted in improved WOMAC scores at 1 year postoperatively in 70% of patients with KOA. This technique was safe and affordable and ensured consecutive infiltrations with the same product to each patient.
- 1 February 2020
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 59 (1) , 102716
Platelet-derived bio-products: Classification update, applications, concerns and new perspectives
- 1 February 2020
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 59 (1) , 102716
Platelet-derived bio-products: Classification update, applications, concerns and new perspectives
- Open Access
- 25 November 2019
- Published by University of Leon
Diagnóstico precoz de amiloidosis primaria mediante biopsia de ligamento transverso del carpo durante la cirugía en el síndrome del túnel carpiano = Early diagnosis of primary amyloidosis through through transverse carpal ligament biopsy during carpal tunnel syndrome surgery
- 25 November 2019
- Published by University of Leon
Open AccessDiagnóstico precoz de amiloidosis primaria mediante biopsia de ligamento transverso del carpo durante la cirugía en el síndrome del túnel carpiano = Early diagnosis of primary amyloidosis through through transverse carpal ligament biopsy during carpal tunnel syndrome surgery
- 1 March 2017
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 148 (5) , 211-214
Early diagnosis of systemic amyloidosis by means of a transverse carpal ligament biopsy carried out during carpal tunnel syndrome surgery
- 1 March 2017
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 148 (5) , 211-214
Early diagnosis of systemic amyloidosis by means of a transverse carpal ligament biopsy carried out during carpal tunnel syndrome surgery
- 1 March 2017
- Published by Elsevier in Medicina Clinica
- Vol. 148 (5) , 211-214
Diagnóstico precoz de amiloidosis sistémica mediante biopsia de ligamento transverso del carpo durante la cirugía del síndrome del túnel carpiano
- 1 March 2017
- Published by Elsevier in Medicina Clinica
- Vol. 148 (5) , 211-214
Diagnóstico precoz de amiloidosis sistémica mediante biopsia de ligamento transverso del carpo durante la cirugía del síndrome del túnel carpiano